Loading…

Reirradiation of brain metastases with radiosurgery

Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2012-02, Vol.102 (2), p.192-197
Main Authors: Maranzano, Ernesto, Trippa, Fabio, Casale, Michelina, Costantini, Sara, Anselmo, Paola, Carletti, Sandro, Principi, Massimo, Caserta, Claudia, Loreti, Fabio, Giorgi, Cesare
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053
cites cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053
container_end_page 197
container_issue 2
container_start_page 192
container_title Radiotherapy and oncology
container_volume 102
creator Maranzano, Ernesto
Trippa, Fabio
Casale, Michelina
Costantini, Sara
Anselmo, Paola
Carletti, Sandro
Principi, Massimo
Caserta, Claudia
Loreti, Fabio
Giorgi, Cesare
description Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.
doi_str_mv 10.1016/j.radonc.2011.07.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920369216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0167814011003963</els_id><sourcerecordid>920369216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVpabZp_0EJvvVkd0ay9XEJlNCPQKDQNmcha8eJtl4rleyW_feR2SSHXAoDc3nmHeYZxt4jNAgoP-6a5LZx8g0HxAZUA6hfsA1qZWrQWr1km4KpWmMLJ-xNzjsA4CDUa3bCUWsQWm2Y-EEhlaDg5hCnKg5Vn1yYqj3NLpeiXP0L8221IjEv6YbS4S17Nbgx07uHfsquv3z-dfGtvvr-9fLi01XtW5RzrQx10OlhEIPjXYvcuZa0MH7gEjxCz6Uk0SnXG697id5hB71Gg9wbhE6csg_H3LsU_yyUZ7sP2dM4uonikq0p10jDURayPZI-xZwTDfYuhb1LB4tgV1t2Z4-27GrLgrLFVhk7e1iw9HvaPg096inA-RGgcubfQMlmH2jytA2J_Gy3Mfxvw_MAP4YpeDf-pgPlXVzSVBRatJlbsD_Xj60PQwQQRgpxDyRokMU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920369216</pqid></control><display><type>article</type><title>Reirradiation of brain metastases with radiosurgery</title><source>Elsevier</source><creator>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</creator><creatorcontrib>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</creatorcontrib><description>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2011.07.018</identifier><identifier>PMID: 21880387</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - secondary ; Brain Neoplasms - surgery ; Brain radionecrosis ; Contrast Media ; Dose-Response Relationship, Radiation ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Particle Accelerators ; Proportional Hazards Models ; Radiosurgery ; Radiosurgery - instrumentation ; Radiosurgery - methods ; Radiotherapy Dosage ; Recurrent brain metastases ; Reirradiation ; Retreatment ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Whole brain radiotherapy</subject><ispartof>Radiotherapy and oncology, 2012-02, Vol.102 (2), p.192-197</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</citedby><cites>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21880387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maranzano, Ernesto</creatorcontrib><creatorcontrib>Trippa, Fabio</creatorcontrib><creatorcontrib>Casale, Michelina</creatorcontrib><creatorcontrib>Costantini, Sara</creatorcontrib><creatorcontrib>Anselmo, Paola</creatorcontrib><creatorcontrib>Carletti, Sandro</creatorcontrib><creatorcontrib>Principi, Massimo</creatorcontrib><creatorcontrib>Caserta, Claudia</creatorcontrib><creatorcontrib>Loreti, Fabio</creatorcontrib><creatorcontrib>Giorgi, Cesare</creatorcontrib><title>Reirradiation of brain metastases with radiosurgery</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - surgery</subject><subject>Brain radionecrosis</subject><subject>Contrast Media</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Particle Accelerators</subject><subject>Proportional Hazards Models</subject><subject>Radiosurgery</subject><subject>Radiosurgery - instrumentation</subject><subject>Radiosurgery - methods</subject><subject>Radiotherapy Dosage</subject><subject>Recurrent brain metastases</subject><subject>Reirradiation</subject><subject>Retreatment</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Whole brain radiotherapy</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkU1r3DAQhkVpabZp_0EJvvVkd0ay9XEJlNCPQKDQNmcha8eJtl4rleyW_feR2SSHXAoDc3nmHeYZxt4jNAgoP-6a5LZx8g0HxAZUA6hfsA1qZWrQWr1km4KpWmMLJ-xNzjsA4CDUa3bCUWsQWm2Y-EEhlaDg5hCnKg5Vn1yYqj3NLpeiXP0L8221IjEv6YbS4S17Nbgx07uHfsquv3z-dfGtvvr-9fLi01XtW5RzrQx10OlhEIPjXYvcuZa0MH7gEjxCz6Uk0SnXG697id5hB71Gg9wbhE6csg_H3LsU_yyUZ7sP2dM4uonikq0p10jDURayPZI-xZwTDfYuhb1LB4tgV1t2Z4-27GrLgrLFVhk7e1iw9HvaPg096inA-RGgcubfQMlmH2jytA2J_Gy3Mfxvw_MAP4YpeDf-pgPlXVzSVBRatJlbsD_Xj60PQwQQRgpxDyRokMU</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Maranzano, Ernesto</creator><creator>Trippa, Fabio</creator><creator>Casale, Michelina</creator><creator>Costantini, Sara</creator><creator>Anselmo, Paola</creator><creator>Carletti, Sandro</creator><creator>Principi, Massimo</creator><creator>Caserta, Claudia</creator><creator>Loreti, Fabio</creator><creator>Giorgi, Cesare</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Reirradiation of brain metastases with radiosurgery</title><author>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - surgery</topic><topic>Brain radionecrosis</topic><topic>Contrast Media</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Particle Accelerators</topic><topic>Proportional Hazards Models</topic><topic>Radiosurgery</topic><topic>Radiosurgery - instrumentation</topic><topic>Radiosurgery - methods</topic><topic>Radiotherapy Dosage</topic><topic>Recurrent brain metastases</topic><topic>Reirradiation</topic><topic>Retreatment</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Whole brain radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maranzano, Ernesto</creatorcontrib><creatorcontrib>Trippa, Fabio</creatorcontrib><creatorcontrib>Casale, Michelina</creatorcontrib><creatorcontrib>Costantini, Sara</creatorcontrib><creatorcontrib>Anselmo, Paola</creatorcontrib><creatorcontrib>Carletti, Sandro</creatorcontrib><creatorcontrib>Principi, Massimo</creatorcontrib><creatorcontrib>Caserta, Claudia</creatorcontrib><creatorcontrib>Loreti, Fabio</creatorcontrib><creatorcontrib>Giorgi, Cesare</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maranzano, Ernesto</au><au>Trippa, Fabio</au><au>Casale, Michelina</au><au>Costantini, Sara</au><au>Anselmo, Paola</au><au>Carletti, Sandro</au><au>Principi, Massimo</au><au>Caserta, Claudia</au><au>Loreti, Fabio</au><au>Giorgi, Cesare</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reirradiation of brain metastases with radiosurgery</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>102</volume><issue>2</issue><spage>192</spage><epage>197</epage><pages>192-197</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>21880387</pmid><doi>10.1016/j.radonc.2011.07.018</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-8140
ispartof Radiotherapy and oncology, 2012-02, Vol.102 (2), p.192-197
issn 0167-8140
1879-0887
language eng
recordid cdi_proquest_miscellaneous_920369216
source Elsevier
subjects Adult
Aged
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Brain Neoplasms - surgery
Brain radionecrosis
Contrast Media
Dose-Response Relationship, Radiation
Female
Hematology, Oncology and Palliative Medicine
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Particle Accelerators
Proportional Hazards Models
Radiosurgery
Radiosurgery - instrumentation
Radiosurgery - methods
Radiotherapy Dosage
Recurrent brain metastases
Reirradiation
Retreatment
Retrospective Studies
Survival Rate
Treatment Outcome
Whole brain radiotherapy
title Reirradiation of brain metastases with radiosurgery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A28%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reirradiation%20of%20brain%20metastases%20with%20radiosurgery&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Maranzano,%20Ernesto&rft.date=2012-02-01&rft.volume=102&rft.issue=2&rft.spage=192&rft.epage=197&rft.pages=192-197&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2011.07.018&rft_dat=%3Cproquest_cross%3E920369216%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=920369216&rft_id=info:pmid/21880387&rfr_iscdi=true